Protective medical industry had undergone a process of weeding out the weak and retaining the strong. As the market consolidates and evolves rapidly, Action Medical has expanded its Hong Kong production line of quality face masks and developed its local and overseas sales business in earnest. Using Hong Kong as a base, it is also actively setting foot into related protective medical product fields and expanding its business into emerging markets.

On 20 June 2025, the European Commission (“Commission”) announced that it has decided to exclude Chinese companies from EU government purchases of medical devices exceeding €5 million. This measure follows the conclusions of the first investigation under the EU’s International Procurement Instrument.

Medical services extend beyond traditional treatments to include a comprehensive array of healthcare offerings, such as assisted reproduction. In an interview with HKTDC Research, Incinta Medical Group elaborated that assisted reproduction services encompass several specialized medical areas. With its diversified biopharmaceutical industry and international business environment, Hong Kong is strategically positioned to support the company's efforts in pursuing technological collaborations for further expansion.

The Ministry of Industry and Information Technology and six other government departments jointly released an Implementation Plan for the Smart Digital Transformation of the Pharmaceutical Industry (2025-2030) on 24 April. The plan aims to formulate or revise 30 smart digital standards for the pharmaceutical industry, develop and promote over 100 high-performance products in areas such as testing equipment and pharmaceutical industry software, create more than 100 typical scenarios for the application of smart digital technologies in the pharmaceutical industry, and establish over 100 smart digital medical device factories by 2027. Main tasks include strengthening the development and application of smart digital products in the pharmaceutical industry, launching pilot programmes for an “AI-empowered whole pharmaceutical industry chain”, and encouraging leading pharmaceutical companies to form consortiums with healthcare institutions, scientific research institutions, upstream and downstream enterprises and large clients and establish application scenarios across the whole pharmaceutical industry chain. Smart digital pharmaceutical industry zones will be established and guided to focus on aspects such as smart management and network collaboration. Efforts will also be made on solicitation, selection and proficiency testing in relation to smart regulatory tools and on promoting the sharing of information in the industry.